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ABSTRACT
To elucidate the mechanisms of cationic protein-induced
airway hyperresponsiveness (AHR), the airway response
to methacholine, and the concentrations of throm-
boxane B2 (TXB2) and 6-keto-PGF1a in the broncho-
alveolar lavage fluid (BALF) of guinea-pigs were
measured after inhalation of poly-L-lysine (P-L-L). The
airway responsiveness (AR) was evaluated by specific
airway resistance. The inhalation of P-L-L significantly
enhanced AR to methacholine, and increased TXB2 and
6-keto-PGF1a in the BALF. The enhanced AR and the
increase of TXB2 and 6-keto-PGF1a were both signifi-
cantly inhibited by pretreatment with low molecular
weight heparin (LMWH; anionic protein; 10 mg/mL for
6 min inhalation). Furthermore, thromboxane (TX) syn-
thase inhibitor (ozagrel), thromboxane A2 (TXA2) recep-
tor antagonist (ONO-3708), and bradykinin B2 receptor
antagonist (BBRA; Na-adamantaneacetyl-D-Arg [Hyp3,
Thi5,8, D-Phe7]-bradykinin) inhibited the cation-induced
AHR. BBRA significantly inhibited the increase of those
mediators in the BALF. The data suggest that TXA2, which
is newly generated by the stimulation of the bradykinin
B2 receptor after inhalation of cationic proteins, plays
an important role in cationic protein-induced AHR in
guinea pigs.
Key words: airway hyperresponsiveness, bradykinin,
cationic protein, low molecular weight heparin, poly-
L-lysine, 6-keto-PGF1a, thromboxane A2.
INTRODUCTION
Bronchial asthma is considered to be a form of eosino-
philic desquamative bronchitis1 and eosinophil-derived
granuloproteins play an important role in airway hyper-
responsiveness (AHR).2 It has been demonstrated that
major basic protein (MBP), one of the eosinophil-derived
cationic granuloproteins, damages the bronchial epithe-
lium of guinea-pigs in vitro,3,4 and increases airway
responsiveness in guinea-pigs in vitro,5 in primates in vivo,6
and in rats in vivo.7 These investigators3–7 suggested that
epithelium desquamation is the most important phen-
omenon in MBP-induced AHR.
Barker et al.8 demonstrated that AHR induced by MBP
was suppressed by pretreatment with polyanionic pro-
teins, suggesting that cationic charges derived from
MBP enhance the airway responsiveness. Synthetic
cationic proteins also induce AHR, which was similarly
inhibited by polyanionic proteins such as heparin and
poly-L-glutamine in rats in vivo9,10 and in guinea-pigs
in vitro.10,11 However, epithelial desquamation was not
observed in cation-induced AHR, which suggested that
the cation-induced AHR may have been the result of
epithelial dysfunction and not epithelial desquamation.
In epithelial dysfunction induced by cationic proteins,
the release of neuropeptides12 and the increased genera-
tion of bradykinin13 have been shown. Arachidonic acid
(AA) metabolites may also contribute to the mecha-
nism of cation-induced AHR,14 because cationic proteins
stimulate the release of prostaglandins in guinea-pig
epithelial cells15,16 and in cultured mouse fibroblasts.17
In order to elucidate the mechanism of the AHR
induced by cationic proteins in guinea-pigs, we investi-
gated the effects of an H1 antagonist, a thromboxane (TX)
synthase inhibitor, a thromboxane A2 (TXA2) receptor
antagonist, a neurokinin receptor antagonist, and a
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bradykinin receptor antagonist on the AHR induced in
guinea pigs by poly-L-lysine (P-L-L), which has potent
strong cationic charges.
In addition, in order to investigate the participation of
the products from the cyclo-oxygenase pathway in the
cation-induced AHR, we measured the airway resistance
and the concentrations of thromboxane B2 ((TXB2), the
stable metabolite of TXA2) and 6-keto-PGF1a (the stable




Male Hartley specific pathogen-free guinea-pigs (Japan
SLC Co., Hamamatsu, Japan) weighing 350–500 g were
used for this study. The guinea-pigs were housed four to a
cage in standard cages and were fed with standard lab
chow (CG-7, Japan Kurea Co., Osaka, Japan). They were
kept in a room maintained at 23 ± 2°C and at 55 ± 5%
humidity. All animal experiments were conducted accord-
ing to the ‘Guidelines for animal experimentation at
the Kobe University School of Medicine’ (permission
number: P931012).
Drugs
Poly-L-lysine, pyrilamine, low molecular weight heparin
(LMWH) and bradykinin B2 receptor antagonist ((BBRA) Na-
adamantaneacetyl-D-Arg-[Hyp3,Thi5,8 D-Phe7]-bradykinin)
were obtained from Sigma Chemical Co. (St Louis, MO,
USA). FK-888 was donated by the Fujisawa Pharma-
ceutical Co. (Tokyo, Japan). Ozagrel and ONO-3708
were donated by Ono Pharmaceutical Co. (Osaka, Japan).
Dimethyl sulfoxide (DMSO) and methacholine were
obtained from Wako Pure Chemical Industries (Osaka,
Japan). Thiopental sodium was from Tanabe Chemical Co.
(Osaka, Japan) and saline was from Otsuka Chemical
Co. (Tokyo, Japan).
Experimental protocol
Poly-L-lysine was dissolved in sterile physiological saline
and prepared at the final concentration of 2.5 mg/mL.
The guinea-pig was placed in a chamber box and kept
awake. It breathed spontaneously. Aerosolized P-L-L
was delivered into the chamber box from an ultrasonic
nebulizer (Model NE-U12, Omron Co., Tokyo, Japan) for
6 min. One hour later, the animal was transferred to
another box for the measurement of airway response
to methacholine. In the negative control group, saline in
place of P-L-L was inhaled.
The effects of LMWH, an anionic substance, on the
P-L-L-induced AHR were examined in two groups: the
LMWH group, with an inhalation of LMWH for 6 min
(10 mg/mL) 1 h before P-L-L inhalation; and the control
group, whereby saline in place of LMWH was inhaled.
FK-888, neurokinin NK1 receptor antagonist, dissolved
in DMSO was injected intraperitoneally at a dose of
1 mg/kg or 10 mg/kg of FK-888 1 h before P-L-L inhala-
tion. In the negative control group, DMSO in place of
FK-888 was injected.
The effects of pyrilamine (H1 antagonist), ozagrel
(TX synthase inhibitor), and ONO-3708 (TXA2 receptor
antagonist) on the P-L-L-induced AHR were examined.
These substances were each dissolved in sterile physio-
logical saline and injected separately into the intraperi-
toneal cavity of guinea-pigs 1 h before P-L-L inhalation.
The administered doses were 10 mg/kg of pyrilamine,
20 mg/kg and 100 mg/kg of ozagrel, and 10 mg/kg of
ONO-3708. In the negative control group, saline was
injected in place of these substances.
Bradykinin B2 receptor antagonist was dissolved in
the sterile physiological saline and injected into the
intraperitoneal cavity of guinea pigs 15 min before P-L-L
inhalation. The final concentrations were 100 nmol/kg
and 1000 nmol/kg. In the negative control group,
saline in place of BBRA was injected into the intra-
peritoneal cavity.
We performed the assessment of airway responsive-
ness and of BALF using the different guinea-pig groups.
The experimental protocol is summarized in Figure 1.
Assessment of the airway responsiveness
The airway responsiveness to methacholine was assessed
1 h after P-L-L inhalation while the animals were awake
and breathing spontaneously. Specific airway resistance
(SRaw) was measured using a double-flow plethysmo-
graph (Model PLYUN2P, Buxco, Sharon, CT, USA), with
the method of Pennock et al.18 Each animal was placed
in the two-compartment plethysmograph with its head
protruding from the front of the chest box and into the
head box through a hole covered by a rubber faceplate.
Changes in the thoracic gas volume and in the gas
volume at the mouth were measured with a differential
pressure transducer (Model DP45–14, Buxco), and SRaw
was calculated using the respiratory analyzer (Model
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PMUA + SAR, Buxco). After stabilization of the baseline
SRaw, aerosolized 0.9% saline and doubled concentra-
tions of methacholine (0.03–4 mg/mL) with the ultra-
sonic nebulizer were introduced into the head box via
bias flow. Each dose was inhaled for 1 min and peak
SRaw was determined in the following 2 min. Increased
concentrations of methacholine were delivered until
the SRaw reached more than twice the baseline value.
The dose of methacholine required to increase SRaw to
twice its baseline value was used to determine the PC100.
The SRaw values were transformed to their normal loga-
rithms prior to statistical analyses because they showed
logarithmic normal distribution.
Bronchoalveolar lavage
Bronchoalveolar lavage (BAL) was performed using other
guinea-pigs 1 h after saline inhalation or 1 h after P-L-L
inhalation.
Guinea-pigs were killed by an overdose, by intraperito-
neal injection, of 2 mL thiopental sodium, 25 mg/mL.
The trachea was carefully exposed after incision. A
21-gauge cannula was inserted through an incision in
the upper trachea and tied in place with surface thread.
Lavage was performed by introducing 3 mL of sterile
physiological saline into the lungs via tracheal cannula
and carefully withdrawing the fluid. This procedure was
repeated three times. The BALF was centrifuged at 800
r.p.m. for 3 min, and the cell pellet was resuspended in
0.5 mL physiological saline. An air-dried slide prepara-
tion was then made at 800 r.p.m. for 3 min in a cytospin.
This was stained with Diff-Quik, and a differential cell
count of at least 400 cells was made according to
standard morphological criteria. The numbers of cells
recovered per guinea-pig was calculated and expressed
as the mean and standard error of mean (SEM) for each
treatment group.
Measurement of TXB2 and 6-keto-PGF1a
The supernatant of the BALF was used for measuring
TXB2 and 6-keto-PGF1a. Both mediators were analyzed
by an enzyme-linked immunosorbent assay (ELISA)
method at the Laboratory of Ono Pharmaceutical
Co., Ltd.
To investigate the effect of LMWH and BBRA on the
production of TXB2 and 6-keto-PGF1a, we recovered
BALF 1 h after P-L-L inhalation in a control group and in
a group pretreated with LMWH or with BBRA.
Statistics
Data are expressed as the geometric means ± geo-
metric standard error of the means (SEM). Statistical
analysis of PC100 was performed on logarithmically
transformed data, because it showed logarithmic
normal distribution. Comparisons between two groups
were performed using Student’s t-test. Comparisons
among more than two groups were performed using
two-tailed analysis of variance (ANOVA) and post-
comparison was performed using Fisher’s PLSD. All
P-values were two-tailed, and a P-value < 0.05 was
considered to be significant.
RESULTS
Airway responsiveness
The effects of P-L-L on airway response and the effects of
LMWH on cation-induced AHR are summarized in Table 1.
The inhalation of P-L-L significantly increased the airway
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Fig. 1 Experimental protocol for assessment of airway res-
ponsiveness and of bronchoalveolar lavage fluid (BALF). P-L-L,
poly-L-lysine; LMWH, low molecular weight heparin; i.p.
Table 1. Effects of poly-L-lysine and low molecular weight
heparin (LMWH) on airway response
Pretreatment Inhalation Number -Log PC100
of animals
Saline 8 0.366 ± 0.104
Saline P-L-L 8 0.817 ± 0.199*
LMWH P-L-L 8 0.410 ± 0.072**
Results are expressed as the mean ± SEM. *P < 0.01 compared
with saline inhalation; **P < 0.05 compared with saline pretreatment
with P-L-L inhalation; P-L-L, poly-L-lysine.
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Fig. 2 The effects of pretreatment of FK-888 or pyrilamine on
the airway hyperresponsiveness induced by poly-L-lysine (P-L-L).
(a) Pretreatment of dimethyl sulfoxide (h), FK-888 1 mg/kg ( )
or 10 mg/kg ( ). (b) Pretreatment of saline (h) or pyrilamine
10 mg/kg ( ). Results are expressed as the mean ± SEM of
-PC100 for eight animals; NS, not significant.
Fig. 3 The effects of ozagrel and ONO-3708 on the airway
hyperresponsiveness induced by P-L-L. (a) Pretreatment of
saline (h), ozagrel 20 mg/kg ( ) or ozagrel 100 mg/kg ( ).
(b) Pretreatment of saline (h) or ONO-3708 10 mg/kg ( ).
Results are expressed as the mean ± SEM of -PC100 for eight
animals; NS, not significant.
responsiveness to methacholine compared with saline
inhalation. Pretreatment of LMWH significantly inhibited
the AHR.
Figure 2 shows the effects of FK-888 and pyrilamine
on P-L-L-induced AHR. Pretreatment of FK-888 and of
pyrilamine did not inhibit P-L-L-induced AHR.
The effects of ozagrel and ONO-3708 on P-L-L-
induced AHR are exhibited in Fig. 3. Although the
pretreatment with low-dose ozagrel (20 mg/kg) did not
have a significant inhibitory effect on P-L-L-induced AHR,
the high-dose ozagrel (100 mg/kg) significantly inhibited
the P-L-L-induced AHR (Fig. 3a). Further, 10 mg/kg of
ONO-3708 significantly inhibited P-L-L-induced AHR
(Fig. 3b).
The effects of BBRA on P-L-L-induced AHR are shown in
Fig. 4. The pretreatment of low-dose BBRA (100 nmol/kg)
did not show a significant inhibitory effect on P-L-L-
induced AHR, but high-dose BBRA (1000 nmol/kg)
inhibited it significantly.
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Fig. 4 The effect of bradykinin B2 receptor antagonist
(BBRA; Na-adamantaneacetyl-D-Arg-[Hyp3,Thi5,8, D-Phe7]-
bradykinin) on the airway hyperresponsiveness induced by
P-L-L. Pretreatment of saline (h), BBRA 100 nmol/kg ( ) or
BBRA 1000 nmol/kg ( ). Results are expressed as the
mean ± SEM of -PC100 for eight animals; NS, not significant.
Fig. 5 The effect of the pretreatment with low molecular
weight heparin (LMWH) and bradykinin B2 receptor antagonist
(BBRA) on (a) TXB2 and (b) 6-keto-PGF1a concentrations in the
BALF to inhalation of poly-L-lysine (P-L-L).
Differential cell counts in bronchoalveolar
lavage fluid
The inhalation of P-L-L did not affect the differential cell
count in the BALF. Epithelial cells in BALF had a tendency
to increase by P-L-L inhalation.
Concentration of TXB2 and 6-keto-PGF1a in
bronchoalveolar lavage fluid
P-L-L inhalation significantly increased cyclo-oxygenase
products, TXB2 and 6-keto-PGF1a, in the BALF compared
with saline inhalation.
The pretreatments of LMWH and BBRA inhibited the
increase of the cyclo-oxygenase products in the BALF
induced by P-L-L (Fig. 5a,b).
DISCUSSION
The results showed that synthetic cationic proteins induced
airway hyperresponsiveness in guinea pigs, and that this
AHR resulted from the stimulation of the cyclo-oxygenase
pathway mediating the bradykinin B2 receptor.
Various chemical mediators and neuropeptides con-
tribute to the mechanism of cation-induced AHR.12,13,19
Santana et al.19 have reported that inflammatory changes
induced by poly-L-arginine, another type of polycation,
are dependent on the mast cell activation and the electro-
static interactions in rats. The pretreatment of pyrilamine
(an H1 antagonist) in the present study did not inhibit the
P-L-L-induced AHR, suggesting that the H1 receptor did
not participate in the P-L-L-induced AHR in guinea-pigs.
Therefore, the electrostatic interaction might play an
important role in the P-L-L-induced AHR. In addition, sub-
stance P, which was released from sensory nerves, played
an important role in the cationic protein-induced AHR in
rats through stimulating the neurokinin NK1 receptor.12
However, FK-888, which is a potent, competitive and
selective antagonist for NK1 receptor,20 did not inhibit the
P-L-L-induced AHR in the present study. We also suggest
that the neurokinin NK1 receptor does not participate in
the P-L-L-induced AHR in guinea-pigs.
Arachidonic acid metabolites may contribute to the
mechanism of cation-induced AHR because major basic
protein and synthetic polycations in the guinea-pig epi-
thelium produce bronchoconstrictor prostanoids,15,16 and
cationic proteins stimulate the release of prostaglandins in
cultured mouse fibroblasts.17 Coincubation of major basic
proteins in the presence of AA with guinea-pig epithelial
cells shows the decrease of prostaglandin E2 and the
increase of thromboxane B2. The mechanism of the pro-
duction of prostanoids stimulated with major basic protein
and P-L-L is not related to cytotoxic effects but to charge
interactions.15 Of the prostanoids, TXA2, which is a potent
mediator of airway inflammation, has been involved in
AHR.21 In contrast, PGI2, which is a relaxant mediator,22
acts against the AHR.23 Therefore, we examined the
effect of a TX synthase inhibitor (ozagrel) and a TXA2
receptor antagonist (ONO-3708), and measured TXB2
and 6-keto-PGF1a in BALF after P-L-L inhalation.
It has been reported that the concentrations used in the
present study of ozagrel and ONO-3707 are indeed
effective in inhibiting the bronchoconstriction.24,25 Our
results showed that the concentrations of TXB2 and
6-keto-PGF1a were both increased in BALF after P-L-L
inhalation, and that both ozagrel and ONO-3708 inhib-
ited AHR. The increased concentration of TXB2 and
6-keto-PGF1a after inhalation of cationic material was
induced by the activation of cyclo-oxygenase pathway.
In our results, the concentration of TXB2 was approxi-
mately five-fold higher than that of 6-keto-PGF1a in BALF
and cation-induced AHR was inhibited by ozagrel and
ONO-3708, suggested that TXA2 plays an important role
in AHR induced by P-L-L inhalation.
It has been shown that bradykinin induces the release
of TXB2 into the BALF of guinea-pigs,26 and that TX
synthase inhibitor and TXA2 receptor antagonist reduce
the bradykinin-induced airflow obstruction in guinea-
pigs.24,27 TXA2 receptor antagonist inhibits the bradykinin-
induced airway contraction in humans,28,29 suggesting
that bradykinin contributes to the modulation of airway
response through TXA2. Bradykinin is an important inflam-
matory mediator that is generated from kininogens by the
actions of plasma and tissue kallikreins.30 Coyle et al.13
have shown that cation-induced AHR is also associated
with bradykinin generation. Experimental study has shown
that incubation of guinea-pig epithelium with major basic
protein or P-L-L augments the production of prostanoids
to the subsequent response to bradykinin.15 In the present
study, BBRA inhibited both the P-L-L-induced AHR and the
production of TXA2 and PGI2 induced by P-L-L inhalation. 
The bradykinin B2 receptor antagonist used in the
present study has a potent inhibitory effect on bradykinin
B2 receptor.31 Bradykinin B2 receptors are present in peri-
pheral airways, including epithelial cells and smooth
muscle cells.32 Epithelial desquamation was not signifi-
cant in BALF and airway histology was not significantly
changed in gross appearance in our preliminary study
after P-L-L inhalation (T Shirotani et al., unpubl. data,
66 T SHIROTANI ET AL.
1995). It is possible that P-L-L-induced AHR is provoked
by prostaglandin formation, especially TXA2, through
BBRA. We did not address the question of what kinds of
airway cells contributed to the production of bradykinin
after inhalation of polycation.
We concluded that poly-L-lysine-induced AHR is due to
the increase of newly generated TXA2 by the stimulation
of the cyclooxygenase pathway mediating bradykinin B2
receptors in airway cells in guinea pigs, without macro-
morphological derangement of bronchial epithelium. An
orally active, non-peptide BBRA has been discovered
recently,33 and how BBRA contributes to the pathophysiol-
ogy of the airway hyperreactivity in bronchial asthma will
be further investigated.
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